Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT‐774312: A novel CRTH2 antagonist

ACT‐774312 is an antagonist of the chemoattractant receptor‐homologous molecule expressed on T helper (Th) 2 cells (CRTH2), in development for the treatment of nasal polyposis or other allergic and type‐2 inflammatory diseases. Placebo, single doses of 1‐1000 mg, or multiple doses of 30‐500 mg eithe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Basic & clinical pharmacology & toxicology 2019-06, Vol.124 (6), p.711-721
Hauptverfasser:	Géhin, Martine, Lott, Dominik, Farine, Hervé, Issac, Milena, Strasser, Daniel, Sidharta, Patricia, Dingemanse, Jasper
Format:	Artikel
Sprache:	eng
Schlagworte:	ACT-774312 Administration, Oral Adult CRTH2 Cytochrome P-450 CYP2C9 - metabolism Dose-Response Relationship, Drug Double-Blind Method entry-into-man study Female Food-Drug Interactions Homology Humans Inflammatory diseases Internalization Male Middle Aged Organic Chemicals - administration & dosage Organic Chemicals - adverse effects Organic Chemicals - pharmacokinetics Organic Chemicals - pharmacology Pharmacodynamics pharmacokinectics Pharmacokinetics Pharmacology Polyposis receptor internalization Receptors, Immunologic - antagonists & inhibitors Receptors, Immunologic - blood Receptors, Prostaglandin - antagonists & inhibitors Receptors, Prostaglandin - blood Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!